Hong-bing B. Cai

Wuhan, 430071, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

The novel SIRT2-targeted PROTAC degraders as the efficient agents for the treatment of ovarian cancer.

The novel SIRT2-targeted PROTAC degraders as the efficient agents for the treatment of ovarian cancer.

Journal: European journal of medicinal chemistry

Published: June 25, 2025

Novel Hsp90-Targeting PROTACs: Enhanced synergy with cisplatin in combination therapy of cervical cancer.

Novel Hsp90-Targeting PROTACs: Enhanced synergy with cisplatin in combination therapy of cervical cancer.

Journal: European journal of medicinal chemistry

Published: February 20, 2024

Predictive value of the Adult Comorbidity Evaluation 27 on adverse surgical outcomes and survival in elderly with advanced epithelial ovarian cancer undergoing cytoreductive surgery.

Predictive value of the Adult Comorbidity Evaluation 27 on adverse surgical outcomes and survival in elderly with advanced epithelial ovarian cancer undergoing cytoreductive surgery.

Journal: European journal of medical research

Published: April 18, 2023

Stapled peptide PROTAC induced significantly greater anti-PD-L1 effects than inhibitor in human cervical cancer cells.

Stapled peptide PROTAC induced significantly greater anti-PD-L1 effects than inhibitor in human cervical cancer cells.

Journal: Frontiers in immunology

Published: March 24, 2023

Multi-omics Analysis Identifies Hypoxia Subtypes and S100A2 as an Immunosuppressive Factor in Cervical Cancer.

Multi-omics Analysis Identifies Hypoxia Subtypes and S100A2 as an Immunosuppressive Factor in Cervical Cancer.

Journal: Reproductive sciences (Thousand Oaks, Calif.)

Published: January 10, 2023

A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer.

A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer.

Journal: Frontiers in pharmacology

Published: November 09, 2022

PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities.

PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities.

Journal: Molecules (Basel, Switzerland)

Published: October 30, 2022

High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells.

High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells.

Journal: Cell death & disease

Published: July 14, 2022

Elastic Net-Based Identification of a Multigene Combination Predicting the Survival of Patients with Cervical Cancer.

Elastic Net-Based Identification of a Multigene Combination Predicting the Survival of Patients with Cervical Cancer.

Journal: Medical science monitor : international medical journal of experimental and clinical research

Published: December 30, 2019

Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo.

Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo.

Journal: Journal of ovarian research

Published: December 12, 2018

Vaginal cuff length during radical hysterectomy is a prognostic factor for stage IB-IIA cervical cancer: a retrospective study.

Vaginal cuff length during radical hysterectomy is a prognostic factor for stage IB-IIA cervical cancer: a retrospective study.

Journal: Cancer management and research

Published: December 05, 2018

Combining differential expression and differential coexpression analysis identifies optimal gene and gene set in cervical cancer.

Combining differential expression and differential coexpression analysis identifies optimal gene and gene set in cervical cancer.

Journal: Journal of cancer research and therapeutics

Published: March 09, 2018

Showing 1-12 of 22

Last Updated: 09/26/2026